Loading quotes...
Forecast
The analysts' average price target is €427.66 (+7.32%). The median is €435.30 (+9.23%).
| Buy |
27 |
| Hold |
11 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Elevance Health boosts revenue and earnings in quarter ended Sept. 30, 2026
For the quarter ended Sept. 30, 2026, Elevance Health reported earnings per share of USD 6.27 compared with USD 5.32 in the prior-year quarter. Revenue rose 1.42 percent to USD 51.43 billion (prior year: USD 50.71 billion). » More on finanzen.net
Elevance Health confirms annual guidance and signals positive Q3, shares rise
Elevance Health’s stock jumped about 5.8% intraday after a regulatory filing in which the company confirmed its adjusted earnings guidance for 2026 of at least $27.00 per share. At the Wells Fargo healthcare conference, Elevance said adjusted EPS for Q3 is above the guidance it gave after Q2; it also reaffirmed an operating cash-flow target of at least $6 billion for 2026 and a 2027 target of at least 12% adjusted EPS growth versus 2026. Today’s ex-dividend date (dividend $1.72 per share) may have prompted additional buying interest. » More on de.investing.com
Elevance Health confirms 2026 EPS target and leans on Carelon growth for margin protection
Elevance Health confirms an adjusted EPS target of at least $27.00 for 2026 despite significant one-off items. The company is realizing substantial synergies through the rapid expansion of its profitable services arm, Carelon. CEO Gail Boudreaux prioritizes margin protection and is deliberately forgoing unprofitable member growth. The operating model remains a combination of a traditional insurance business and a high-growth services segment. » More on finanzen.net
Elevance Health raises full-year EPS outlook after Q2 profit of $1.45 billion
Elevance Health reported second-quarter net income of $1.45 billion ($6.71 per share), a year-over-year decline, as its benefit expense ratio rose to 89.7% due to elevated medical costs in government businesses. Revenue grew 1.4% to $50.47 billion and membership fell to 44.9 million. Strong operating performance and favorable benefit expense trends prompted the company to raise 2026 adjusted EPS guidance to at least $27.00 and its full-year EPS outlook to at least $20.10 per share. Management highlighted disciplined execution, improved individual ACA results, and increased investment in medical cost management and Carelon services. » More on forbes.com
Margin pressure at Elevance Health cuts margins and sends insurer shares tumbling
Elevance Health reported Q2 2026 revenue rising to $50.47 billion and adjusted EPS of $7.45, but the operating margin in its Health Benefits segment fell from 5.0% to 3.6%. The stock lost 6.7% in premarket trading after it emerged the result was supported by a one‑off item of $0.80 per share and the core business is under significant pressure. Operating income in the Health Benefits segment nearly halved, membership slipped slightly to 44.95 million, and analysts expect declining revenues. Margin concerns also weighed on shares across the industry, including UnitedHealth, Molina, Humana, Centene and CVS. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 45.4bn | 5.07% |
| Gross profit | 7.07bn | 33.98% |
| Net profit | 1.21bn | 18.94% |
| EBITDA | 2.22bn | 21.53% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €84.45bn |
Number of shares | 216.06m |
52-week high/low | €410.00 - €250.02 |
Dividend yield | 1.46% |
Dividends TTM | €5.97 |
Beta | 0.71 |
P/E ratio | 18.30 |
PEG ratio | -4.31 |
P/B ratio | 2.09 |
P/S ratio | 0.46 |
Company profile
Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small groups, individuals, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as pharmacy benefits management, dental, vision, life and disability insurance benefits, and analytics-driven personal health care. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2021, it served 45 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
| Name | Elevance Health Inc. |
| CEO | Gail Koziara Boudreaux |
| Headquarters | Indianapolis,
in USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| IPO | 30/10/2001 |
| Employees | 96,615 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | ELV |
London Stock Exchange | 0HG8.L |
NYSE | ANTM |
Frankfurt | A58.F |
Düsseldorf | A58.DU |
Milan | 1ANTM.MI |
London | 0HG8.L |
SIX | A58.SW |
München | A58.MU |
Wien | ANTM.VI |